SCHEMBL5344796

SCHEMBL5344796

COC(=O)Nc1ccc(C2=C(C(=O)O)N3C(=O)[C@H]([C@@H](C)O[Si](C)(C)C)[C@H]3C2)cc1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 3/20 0.34
BECN1 Q14457 2/20 0.34
SMN1; SMN2 Q16637 3/20 0.32
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32
PDE3B Q13370 2/20 0.32
PDE3A Q14432 2/20 0.32
HPGD P15428 1/20 0.32
ESR1 P03372 1/20 0.32
CHRM1 P11229 1/20 0.32
SLC6A4 P31645 1/20 0.32
KCNH2 Q12809 1/20 0.32
SLC29A1 Q99808 1/20 0.32
PIK3CA P42336 2/20 0.31
MTOR P42345 2/20 0.31
ALDH1A1 P00352 1/20 0.31
GRM5 P41594 1/20 0.30
PSMB8 P28062 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5353362 0.88 BCL2 (0.39) BCL2BECN1KDM4ELMNAPDE3B
SCHEMBL5346495 0.87 MTOR (0.38) KCNH2PIK3CAMTOR
SCHEMBL5343622 0.87 KDM4E (0.40) BCL2BECN1SMN1; SMN2KDM4ELMNA
SCHEMBL5346815 0.86 MAPK1 (0.41) SMN1; SMN2LMNAHPGDALDH1A1
SCHEMBL14517782 0.85 GAA (0.35) BCL2PDE3BPDE3A
SCHEMBL5340133 0.84 ADAMTS4 (0.35) SMN1; SMN2KDM4ELMNAHPGDESR1
SCHEMBL5353135 0.82 RAB9A (0.41) SMN1; SMN2KDM4ELMNAHPGDALDH1A1
SCHEMBL5338872 0.82 KDM4E (0.36) KDM4ELMNAESR1CHRM1SLC6A4
SCHEMBL5352932 0.81 MAPK1 (0.34) KDM4ELMNAHPGDESR1CHRM1
SCHEMBL5353271 0.80 LMNA (0.34) SMN1; SMN2KDM4ELMNAESR1CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7205291-B2 High mouth absorption; antibiotics against gramnegative, grampositive bacteria espscially Staphlococcus pneumonia, Hemophilus influenza DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-17 US disclosed
US-20050020566-A1 Novel carbapenem compounds DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-01-27 US disclosed
EP-1443047-A1 NOVEL CARBAPENEM COMPOUNDS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020566-A1 Novel carbapenem compounds HPN, PRSS1, BPGM BCL2 3597/4885BECN1 793/4885SMN1; SMN2 2613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.